Klindex Adverse Reactions

Gastrointestinal: CDAD and colitis/pseudomembranous colitis [frequently accompanied by fever and leukocytosis; rarely, reactive polyarthritis and protein-losing enteropathy (in elderly patients)], nausea, vomiting, diarrhea, abdominal pain/cramps, tenesmus, flatulence, bloating, anorexia, weight loss, esophagitis, esophageal ulcers.
Dermatologic and Hypersensitivity Reactions: Generalized mild to moderate morbilliform-like (maculopapular) skin rashes, rash, urticaria, pruritus, fever, hypotension, anaphylaxis/anaphylactoid reactions; erythema multiforme, Stevens-Johnson syndrome; exfoliative and vesiculobullous dermatitis, vesiculobullous rashes, serious cutaneous adverse reaction (SCAR), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), drug reaction eosinophilia and systemic symptoms (DRESS).
Hepatobiliary and Renal: Jaundice, hepatic damage, transient increases in serum bilirubin, alkaline phosphatase, aspartate aminotransferase (AST); although no direct relationship of clindamycin to renal damage has been established, rare cases of renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria have been observed, abnormalities in liver function tests.
Genitourinary: Vaginal infection/vaginitis.
Hematologic: Transient neutropenia (leukopenia), eosinophilia, thrombocytopenia, and agranulocytosis have been reported although no direct etiologic relationship to concurrent clindamycin therapy could be made in any of these instances. However, in clindamycin/primaquine combination studies, serious hematologic toxicities (grade III, grade IV neutropenia or anemia, platelet counts <50 x 109/L, or methemoglobin levels of ≥ 15%) have been observed. Leukocytoclastic angiitis has also been reported.
Musculoskeletal: Polyarthritis.
Nervous: Dysgeusia.
Other Adverse Effects: lymphadenitis.